NASDAQ$IART

Integra LifeSciences Holdings Corporation · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Briefing

Reported a decrease in revenue and earnings due to the impact of COVID-19.

Integra LifeSciences reported a decrease in revenue by 1.5% and a decline in GAAP earnings per diluted share from $0.38 to $0.11 compared to the prior year, largely due to the negative impact of COVID-19 which led to deferral of non-emergent surgical procedures.

  • Reported revenues were $354.3 million, a decrease of (1.5)% on a reported basis and (0.1)% on an organic basis, compared to the prior year.
  • GAAP earnings per diluted share were $0.11, compared to $0.38 in the first quarter of 2019.
  • Adjusted earnings per diluted share were $0.48, compared to $0.65 in the prior year.
  • The company estimates the revenue impact from the decline in surgical procedures related to COVID-19 during the second half of March to be between $20 and $25 million.

Headline financials

Total Revenue

$354M

Previous: $360M-1.5%
EPS (adj)

$0.48

Previous: $0.65-26.2%
Capital Expenditures

-$16.5M

Previous: -$16.1M-2.7%
Free Cash Flow

-$7.34M

Previous: $16.7M-144.0%
Net Income

$9.18M

Previous: $32.8M-72.0%
Operating Income

$27.1M

Previous: $32.3M-16.1%
Gross Profit

$221M

Previous: $231M-4.3%
Cash & Equivalents

$358M

Previous: $157M+127.8%
Total Assets

$3.45B

Previous: $3.21B+7.5%
Stock-Based Comp

$3.75M

Previous: $4.08M-8.2%

Revenue & EPS history

Integra LifeSciences · Revenue · Quarterly

$354M

Q1 2020-1.5%vs Q1 2019
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

Integra LifeSciences · $333M total across 4 segments · Q1 2020

  • Neurosurgery
    $185M+3.0%
  • Wound Reconstruction and Care
    $72.3M-3.6%
  • Instruments
    $46.5M-15.5%
  • Private Label
    $29.1M+6.1%

Forward guidance

Given the existing uncertainty related to COVID-19, the Company’s guidance for the full-year 2020, issued on February 19, 2020, remains withdrawn as announced on April 7, 2020.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2020

Historical avgQ1 2020

-0.2%

Avg return

Earnings day

-1.4%

Avg return

5 days after

-1.8%

Avg return

30 days after

51%

35 / 68 earnings

Positive

+29.2%

Q3 2024

Best reaction

-23.5%

Q3 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+24.4%+31.0%+65.1%
Q4 2025-2.1%-8.9%-20.6%
Q3 2025-23.5%-26.8%-15.0%
Q1 2025-20.9%-27.3%-22.3%
Q4 2024+12.1%+5.3%-0.2%
Q3 2024+29.2%+28.5%+25.1%
Q2 2024-20.4%-23.5%-35.3%
Q1 2024-13.2%-10.0%+9.9%
Q4 2023-16.6%-18.8%-19.9%
Q3 2023-4.5%-5.8%+6.3%
Q2 2023-3.1%-1.1%-9.5%
Q1 2023-6.2%-5.5%-34.7%
Q4 2022+0.2%+0.8%-3.1%
Q3 2022+11.1%+12.7%+21.1%
Q2 2022-1.5%-0.5%-14.8%
Q1 2022+2.9%-0.2%+2.5%
Q4 2021+0.9%+2.6%-2.8%
Q3 2021+7.1%+7.5%-5.3%
Q2 2021-0.2%-0.3%+2.6%
Q1 2021-2.0%-3.4%-9.9%
Q4 2020-4.1%-2.8%-6.2%
Q3 2020-7.0%-4.5%+19.5%
Q2 2020+6.4%+6.6%-5.6%
Q1 2020+1.5%-2.8%+7.9%
Q4 2019+2.9%-0.3%-35.7%
Q3 2019-7.7%-5.1%-2.0%
Q2 2019+12.0%+14.5%+8.0%
Q1 2019-3.1%-2.3%-7.7%
Q4 2018+5.7%+6.1%+6.5%
Q3 2018-12.6%-13.5%-13.9%
Q2 2018-2.3%-2.3%-5.5%
Q1 2018+9.8%+12.7%+16.7%
Q4 2017-4.1%-4.1%+0.7%
Q3 2017-9.1%-8.2%-4.9%
Q2 2017-9.9%-10.7%-10.9%
Q1 2017+4.6%+5.1%+12.1%
Q4 2016-2.1%-1.2%-1.2%
Q3 2016+1.6%-3.4%+3.8%
Q2 2016+6.8%+6.4%+9.0%
Q1 2016+6.7%
Q4 2015+3.8%
Q3 2015+2.8%
Q2 2015-0.1%
Q1 2015+7.5%
Q4 2014+2.3%
Q3 2014-7.5%
Q2 2014+1.0%
Q1 2014-1.6%
Q4 2013-3.9%
Q3 2013+4.4%
Q2 2013-2.2%
Q1 2013+0.2%
Q4 2012-4.8%
Q3 2012-0.3%
Q2 2012+4.1%
Q1 2012+9.4%
Q4 2011+1.2%
Q3 2011-21.8%
Q2 2011-5.3%
Q1 2010+2.1%
Q1 2011+0.8%
Q4 2008-0.7%
Q4 2010-0.7%
Q3 2010+2.2%
Q3 2009+2.2%
Q2 2009+6.2%
Q2 2010+6.2%
Q4 2009+6.2%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro